COPENHAGEN, June 3, 2014 (GLOBE NEWSWIRE) -- ALK today announced that the Company will present at the Goldman Sachs 35 th Annual Global Healthcare Conference in Palos Verdes, CA. Flemming Pedersen, CFO and Executive Vice President, will provide an overview of the Company and its key programmes on Wednesday, 11 June at 2.40 PM Pacific Time (5.40 PM Eastern time). ALK-Abello A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Janet Dally, tel. +1 609-466-0466 Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143 About ALK ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy - a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck (MSD outside the USA and Canada) and Torii to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ OMX Copenhagen. Find more information at www.alk.net.